Nexataf 25 mg Tablet
Nexataf 25 mg Tablet is a trusted medication containing Active Pharmaceutical Ingredient, designed for personal use under the guidance of a healthcare professional. Available for prescription-based international supply with discreet worldwide delivery.
- Active ingredient: Tenofovir Alafenamide (TAF)
- Form: Tablet
- Indication: HIV-1 infection, chronic Hepatitis B
- Manufacturer: Nexataf
This medicine is available to order. Contact us for current pricing and availability.
Request pricing for Nexataf 25 mg Tablet
Our support team will review your request and contact you within 24 hours with pricing and next steps.
Request sent!
What is Tenofovir Alafenamide (TAF)?
How Does It Work?
TAF is a phosphonamidate prodrug that preferentially enters lymphocytes and hepatocytes, where it is converted to tenofovir diphosphate (TFV-DP).
Because activation occurs inside the target cell rather than in plasma, much lower doses achieve equivalent or higher intracellular TFV-DP concentrations than TDF, sparing kidneys and bones from high plasma exposure.
TFV-DP competes with dATP for incorporation into viral DNA, causing premature chain termination of HIV reverse transcription or HBV polymerase activity.
How to Use
Side Effects & Precautions
- Nausea
- Headache
- Fatigue
- Abdominal pain
- Diarrhoea
- Lactic acidosis
- Severe hepatomegaly with steatosis
- Severe acute HBV exacerbation on discontinuation (HBV-infected patients)
- Renal impairment (less common than TDF)
- Concurrent use with TDF-containing products
- Severe hepatic impairment
Generic vs Brand
Storage & Handling
Why Buy From Us
Sourced directly from WHO-GMP certified manufacturers.
Every batch tested for purity and bioequivalence.
Discreet shipping to UK, US, AU, EU and beyond.
Regulated and compliant with international pharmacy standards.
Frequently Asked Questions
Severe acute exacerbation of Hepatitis B has been reported in HBV-infected patients who discontinued TAF. Hepatic function should be monitored closely for at least several months in these patients.
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with nucleoside analogues.
Drug Interactions
| Drug / Substance | Effect | Action |
|---|---|---|
| Rifampicin | Reduces TAF levels — may compromise efficacy | Avoid; consult specialist for alternative |
| Rifabutin | Moderately reduces TAF exposure | Increase TAF dose or avoid |
| P-gp inducers (carbamazepine, St John's Wort) | Reduce TAF plasma levels | Avoid concurrent use |
| TDF-containing products | Duplication of tenofovir — increased toxicity | Do not use concurrently |
Approved Indications
- HIV-1 infection (in combination regimens) FDA / EMA
- Chronic Hepatitis B in adults and children ≥ 2 years (Vemlidy) FDA / EMA